BCTXW

BCTXW

USD

BriaCell Therapeutics Corp. Warrant

$0.049-0.015 (-23.721%)

Reaalajas hind

Healthcare
Biotehnoloogia
Kanada

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.065

Kõrge

$0.054

Madal

$0.033

Maht

0.00M

Ettevõtte fundamentaalnäitajad

Tööstusharu

Biotehnoloogia

Riik

Canada

Kauplemisstatistika

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.0332Praegune $0.049Kõrge $0.054

Seotud uudised

GlobeNewswire

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™ (prostate

Vaata rohkem
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models
GlobeNewswire

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Independent DSMB has identified no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitorFourth consecutive positive DSMB recommendation

Vaata rohkem
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
GlobeNewswire

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

79 clinical sites across 23 US states are currently enrolling patients in BriaCell's pivotal Phase 3 study in metastatic breast cancer (MBC) Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer

Vaata rohkem
BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
GlobeNewswire

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Collaboration with MSK's Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ platform, which includes Bria-BRES+™ for breast cancer PHILADELPHIA

Vaata rohkem
BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer